Edition:
United States

AcelRx Pharmaceuticals Inc (ACRX.O)

ACRX.O on Consolidated Issue listed on NASDAQ Global Market

3.10USD
29 Mar 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.10
Open
$3.10
Day's High
$3.15
Day's Low
$3.07
Volume
216,137
Avg. Vol
213,303
52-wk High
$4.08
52-wk Low
$2.40

ACRX.O

Chart for ACRX.O

About

AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product... (more)

Overall

Beta: 2.72
Market Cap(Mil.): $140.54
Shares Outstanding(Mil.): 45.34
Dividend: --
Yield (%): --

Financials

  ACRX.O Industry Sector
P/E (TTM): -- 49.04 30.15
EPS (TTM): -0.95 -- --
ROI: -42.14 -2.17 13.05
ROE: -310.75 5.20 14.20

BRIEF-European Medicines Agency begins evaluation of marketing application for sublingual Sufentanil

* European Medicines Agency begins evaluation of marketing application for sublingual Sufentanil 30 mcg tablet (ARX-04) for moderate-to-severe acute pain

Mar 28 2017

BRIEF-Acelrx Pharmaceuticals Q4 loss per share $0.21

* Acelrx Pharmaceuticals reports fourth quarter and year end 2016 financial results

Mar 02 2017

BRIEF-Acelrx says U.S. app to market painkiller Dsuvia accepted by FDA

* Acelrx pharmaceuticals' new drug application for dsuvia accepted for filing with pdufa date of october 12, 2017

Feb 27 2017

BRIEF-Acelrx Pharmaceuticals appoints Vincent Angotti as CEO

* Acelrx Pharmaceuticals appoints Vincent J. Angotti chief executive officer

Feb 16 2017

BRIEF-Acelrx Pharma says amended loan and security deal with Hercules Tech II and Hercules Capital Inc

* Among other things, amendment extends interest-only period from October 1, 2016 to April 1, 2017 - SEC filing

Oct 03 2016

More From Around the Web

Earnings vs. Estimates